Competition in the fast growing Indian respiratory products market looks set to intensify with key players and traditional rivals, Cipla and GlaxoSmithKline, each outlining distinct new initiatives in the segment.
Cipla has announced its intent to launch a novel breath-actuated inhaler (BAI) with a dose counter (to be marketed as...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
